Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands

被引:185
作者
Horowitz, MC [1 ]
Xi, YG [1 ]
Wilson, K [1 ]
Kacena, MA [1 ]
机构
[1] Yale Univ, Sch Med, Dept Orthopaed & Rehabil, New Haven, CT 06510 USA
关键词
osteoclastogenesis; osteoblasts; bone resorption;
D O I
10.1016/S1359-6101(00)00030-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Skeletal mass is maintained by a balance between cells which resorb bone (osteoclasts) and cells which form bone (osteoblasts). Bone development and growth is an on-going. life-long process. Bone is formed during embryonic lift, grow's rapidly through childhood, and peaks around 20 years of age (formation exceeds resorption). For humans the skeleton then enters a long period, approximately 40 years, when bone mass remains relatively stable. Skeletal turnover continues but the net effect of resorption and formation on bone mass is zero. For women this ends when they enter menopause and similar bone loss occurs for men. but later in life. These opposite functions: are coupled, resorption precedes formation. and osteoblasts, or their precursors, stromal cells. regulate osteoclast formation and activity. Until recently, the molecular nature of this regulation, was pool ly understood. However, recent observations have identified members of the TNF family of ligands and receptors as critical regulators of osteoclastogenesis. Osteoprotegerin (OPG) a decoy receptor was first identified. Its ligand, receptor activator of nuclear factor-kappaB ligand (RANKL), was quickly found, and shown to be expressed on stromal cells and osteoblasts. Its cognate receptor, RANK, was found to be expressed in high levels on osteoclast precursors. The interaction between RANKL and RANK was shown to be required for osteoclast formation. These observations have provided a molecular understanding of the coupling between osteoclastic bone resorption and osteoblastic bone formation. Moreover. they provide a framework on which to base a clear understanding of normal (e.g. postmenopausal osteoporosis and age associated bone loss) and pathologic skeletal changes (e.g. osteopetrosis. glucocorticoid-induced osteoporosis, periodontal disease, bone metastases. Paget's disease, hyperparathyroidism, and rheumatoid arthritis). (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:9 / 18
页数:10
相关论文
共 74 条
  • [1] Osteoclastogenesis inhibitory factor suppresses osteoclast survival by intetfering in the interaction of stromal cells with osteoclast
    Akatsu, T
    Murakami, T
    Nishikawa, M
    Ono, K
    Shinomiya, N
    Tsuda, E
    Mochizuki, S
    Yamaguchi, K
    Kinosaki, M
    Higashio, K
    Yamamoto, M
    Motoyoshi, K
    Nagata, N
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 250 (02) : 229 - 234
  • [2] A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
    Anderson, DM
    Maraskovsky, E
    Billingsley, WL
    Dougall, WC
    Tometsko, ME
    Roux, ER
    Teepe, MC
    DuBose, RF
    Cosman, D
    Galibert, L
    [J]. NATURE, 1997, 390 (6656) : 175 - 179
  • [3] Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor κB (RANK) receptors
    Arai, F
    Miyamoto, T
    Ohneda, O
    Inada, T
    Sudo, T
    Brasel, K
    Miyata, T
    Anderson, DM
    Suda, T
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (12) : 1741 - 1754
  • [4] Tumor necrosis factor receptor-associated factors (TRAFs) - a family of adaptor proteins that regulates life and death
    Arch, RH
    Gedrich, RW
    Thompson, CB
    [J]. GENES & DEVELOPMENT, 1998, 12 (18) : 2821 - 2830
  • [5] Bekker PJ, 1999, J BONE MINER RES, V14, pS180
  • [6] BENNETT JH, 1991, J CELL SCI, V99, P131
  • [7] Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells
    Brändström, H
    Jonsson, KB
    Ohlsson, C
    Vidal, O
    Ljunghall, S
    Ljunggren, Ö
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 247 (02) : 338 - 341
  • [8] Tumor necrosis factor-α and -β upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells
    Brändström, H
    Jonsson, KB
    Vidal, O
    Ljunghall, S
    Ohlsson, C
    Ljunggren, Ö
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 248 (03) : 454 - 457
  • [9] osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
    Bucay, N
    Sarosi, I
    Dunstan, CR
    Morony, S
    Tarpley, J
    Capparelli, C
    Scully, S
    Tan, HL
    Xu, WL
    Lacey, DL
    Boyle, WJ
    Simonet, WS
    [J]. GENES & DEVELOPMENT, 1998, 12 (09) : 1260 - 1268
  • [10] MESENCHYMAL STEM-CELLS
    CAPLAN, AI
    [J]. JOURNAL OF ORTHOPAEDIC RESEARCH, 1991, 9 (05) : 641 - 650